Nektar Therapeutics (NKTR) Convertible Debt (2010 - 2011)
Nektar Therapeutics (NKTR) recorded quarterly Convertible Debt of $215.0 million in Q2 2011, little changed quarter-over-quarter from $215.0 million in Q1 2011.
Nektar Therapeutics (NKTR) Convertible Debt (2010 - 2011) Analysis & Trends
Nektar Therapeutics' Convertible Debt history runs 2 years deep, the most recent figure standing at $215.0 million for Q2 2011.
- In Q2 2011, Convertible Debt changed N/A year-over-year to $215.0 million; the TTM figure through Jun 2011 stood at $215.0 million (changed N/A YoY), while the FY2010 annual figure was $215.0 million, changed N/A from the prior year.
- Convertible Debt was $215.0 million for Q2 2011 at Nektar Therapeutics, roughly flat from $215.0 million in the prior quarter.
- In the past five years, Convertible Debt ranged from a high of $215.0 million in Q4 2010 to a low of $215.0 million in Q4 2010.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Nektar Therapeutics | 1.51 Bn | 939.55 Mn | 3.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2011 | 214.96 Mn |
| Mar 31, 2011 | 214.96 Mn |
| Dec 31, 2010 | 214.96 Mn |